CKD Albuminuria Treatment

Order a quantitative spot UACR rather than relying on dipstick protein to establish and follow albuminuria. A first-void morning sample is preferred when feasible because it improves initial assessment; repeat an abnormal UACR, preferably using another first-morning specimen, before using albuminuria to direct long-term treatment. acpjournals+1acpjournalsChronic Kidney Disease | Annals of Internal Medicine - ACP JournalsWolters KluwerAlbuminuria in Heart Failure : Cardiology in Review

Assign A1 for UACR <30 mg/g, A2 for 30-299 mg/g, and A3 for ≥300 mg/g. Pair the albuminuria category with eGFR category and CKD cause because albuminuria independently changes kidney and cardiovascular risk even when eGFR is preserved. Wolters Kluwer+2Wolters KluwerRisk of Hospital Readmission among People with CKD : Clinical Journal of the American Society of NephrologyWolters KluwerAlbuminuria in Heart Failure : Cardiology in ReviewKidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...

Screen at least annually with UACR in patients with diabetes, hypertension, cardiovascular disease, or established CKD. An elevated UACR in a patient without an established CKD cause should prompt assessment for an alternative renal diagnosis rather than empiric labeling as diabetic kidney disease. BMJBMJAssessment and management of albuminuria in adults | The BMJ

Refer to nephrology when albuminuria is accompanied by concern for glomerulonephritis, an unknown etiology, severe albuminuria with hematuria, or a calculated 5-year kidney-failure risk above 3%-5%. Referral is also reasonable at UACR >30 mg/mmol, or at UACR >3 mg/mmol when additional risk factors are present. BMJBMJAssessment and management of albuminuria in adults | The BMJ

Do not assume diabetes explains every case of proteinuric CKD. Primary glomerular disorders, including focal segmental glomerulosclerosis, minimal change disease, IgA nephropathy, and membranous nephropathy, can coexist with diabetes; diabetic nephropathy may be accompanied by another kidney disorder in 5%-15% of cases in some series. asn-onlineasn-online[PDF] Chronic Kidney Disease (CKD) - American Society of Nephrology

When the clinical pattern suggests glomerulonephritis or the cause remains unclear, nephrology assessment should determine the need for disease-specific serology, imaging, and kidney biopsy rather than escalating antiproteinuric therapy alone. BMJ+1BMJAssessment and management of albuminuria in adults | The BMJasn-online[PDF] Chronic Kidney Disease (CKD) - American Society of Nephrology

For CKD without diabetes, KDIGO recommends starting an ACE inhibitor or ARB for G1-G4 CKD with A3 albuminuria and suggests either agent for G1-G4 CKD with A2 albuminuria. For CKD with diabetes, start an ACE inhibitor or ARB for G1-G4 CKD with either A2 or A3 albuminuria. Kidney InternationalKidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...

Administer the selected ACE inhibitor or ARB at the highest approved dose the patient tolerates; the evidence base supporting kidney protection used these doses. In patients with diabetes, hypertension, and albuminuria, ACE inhibitor or ARB therapy is first-line antihypertensive therapy, while a dihydropyridine calcium channel blocker or diuretic may be needed alongside it to achieve blood-pressure goals. Kidney International+2Kidney InternationalExecutive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidenceKidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...PubMedProtecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy

Do not combine an ACE inhibitor with an ARB or a direct renin inhibitor in CKD. Combination therapy increases treatment complexity without guideline support and should not be used to pursue a larger albuminuria reduction. Kidney InternationalKidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...

Use an SGLT2 inhibitor in patients with type 2 diabetes and CKD as part of comprehensive kidney and cardiovascular risk reduction. SGLT2 inhibitors reduce albuminuria, attenuate progressive loss of kidney function, and reduce kidney-failure risk in CKD with type 2 diabetes. Wolters Kluwer+1Wolters KluwerBaseline, Early Changes, and Residual Albuminuria : Clinical Journal of the American Society of NephrologyKidney InternationalKDIGO 2020 Clinical Practice Guideline for Diabetes Management ...

Assess response with serial UACR and eGFR rather than requiring complete normalization of albuminuria. Albuminuria reduction occurs early after SGLT2 inhibitor initiation and is sustained during longer treatment; persistent albuminuria after initiation represents residual risk and may support consideration of finerenone when the patient meets its selection criteria. Wolters Kluwer+1Wolters KluwerBaseline, Early Changes, and Residual Albuminuria : Clinical Journal of the American Society of NephrologyKidney InternationalExecutive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

Evidence supports an additive biologic rationale for combining an SGLT2 inhibitor with finerenone in appropriate patients receiving renin-angiotensin system blockade, but definitive evidence defining optimal sequencing and the incremental benefit of adding finerenone to both background therapies remains limited. Kidney International+2Kidney InternationalExecutive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidenceKidney InternationalKDIGO 2022 Clinical Practice Guideline for Diabetes Management ...PubMedClinical Review - Finerenone (Kerendia) - NCBI Bookshelf

Consider finerenone for CKD with type 2 diabetes, persistent albuminuria, eGFR ≥25 mL/min/1.73 m², serum potassium <5.0 mmol/L, and concurrent maximally tolerated ACE inhibitor or ARB therapy. KDIGO identifies finerenone as the nonsteroidal mineralocorticoid receptor antagonist with proven kidney and cardiovascular benefit in this setting. Kidney International+2Kidney InternationalExecutive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidenceKidney InternationalKDIGO 2022 Clinical Practice Guideline for Diabetes Management ...PubMedThe appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice - PMC

Start finerenone 20 mg orally once daily when eGFR is >60 mL/min/1.73 m² and 10 mg orally once daily when eGFR is 25-60 mL/min/1.73 m². Measure serum potassium before initiation and at 4 weeks; potassium surveillance is essential because finerenone increases hyperkalemia risk. PubMedPubMedProtecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy

Finerenone reduced the FIDELIO-DKD composite kidney outcome of kidney failure, sustained ≥40% eGFR decrease, or kidney-related death versus placebo (hazard ratio 0.82, 95% CI 0.73-0.93) and reduced the key cardiovascular composite (hazard ratio 0.86, 95% CI 0.75-0.99). Hyperkalemia-related adverse events were approximately twice as frequent with finerenone as with placebo, reported as 18.3% versus 9.0% in trial data. catalogues ema europa eucatalogues ema europa eu[PDF] Observational Study/Post Authorization Safety Study (PASS ...

If hyperkalemia or clinically meaningful eGFR change emerges during therapy, reassess dose and concurrent potassium-raising therapies; in real-world practice, potassium and eGFR changes were documented reasons for finerenone down-titration. PubMedPubMedDosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study - PMC

Trend UACR and eGFR after initiating or intensifying antiproteinuric therapy. A durable reduction in albuminuria after SGLT2 inhibitor initiation is expected, but residual albuminuria should be interpreted as persistent cardiorenal risk rather than treatment failure by itself. Wolters Kluwer+1Wolters KluwerBaseline, Early Changes, and Residual Albuminuria : Clinical Journal of the American Society of NephrologyKidney InternationalExecutive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

At each reassessment, verify that ACE inhibitor or ARB therapy remains at the highest tolerated approved dose, review serum creatinine and potassium, and determine whether the patient has become eligible for or unsafe for finerenone. Kidney International+2Kidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...PubMedThe appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice - PMCPubMedProtecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy

Escalate to nephrology when albuminuria remains unexplained, hematuria accompanies severe albuminuria, the clinical phenotype suggests glomerulonephritis, or 5-year kidney-failure risk exceeds 3%-5%. The goal is to identify disease-specific therapy or biopsy indications before irreversible loss of kidney function. BMJ+1BMJAssessment and management of albuminuria in adults | The BMJasn-online[PDF] Chronic Kidney Disease (CKD) - American Society of Nephrology